Clinical Trial Update: Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of combining gemcitabine with cetuximab (Erbitux) in patients with resected pancreatic cancer (R0/R1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Carmen Schade-Brittinger | Conditions: Adenocarcinoma | Phase 2 | Status: COMPLETED